Why Won’t My MARCoNS Clear — and Why Does It Keep Coming Back?
You left the moldy building, you took your binders, some symptoms lifted — but you still don’t feel like yourself, and every re-swab comes back positive. If that’s you, you are almost certainly dealing with one of two things: a stubborn biofilm, or an exposure you haven’t fully escaped.
Here is a story we hear almost every week. A patient works hard through the early stages of mold and biotoxin recovery. They get out of the water-damaged building, they start binders, their brain fog begins to lift — and then progress stalls. They still have the fatigue, the sensitivity, the sense of being stuck one step short of themselves. A deep nasal swab comes back positive for MARCoNS. They treat it. They re-swab. It’s still there.
“I’ve done everything right. Why won’t this thing clear?”
It is one of the most common and most demoralizing plateaus in the whole journey of Chronic Inflammatory Response Syndrome (CIRS). And the honest answer is reassuring in a strange way: if your MARCoNS won’t clear, it is very rarely because you are doing something wrong. It is because MARCoNS is genuinely difficult to eradicate — and because a positive re-swab is usually telling you something important about biofilm, ongoing exposure, or a hidden reservoir that a nasal spray alone was never going to fix.
This article walks through what MARCoNS actually is, why it matters so much in CIRS, and — most importantly — the real reasons it resists treatment, drawing on recent clinical data presented by Dr. Margaret DiTulio, decades of laboratory work from Dr. Joseph Musto at MicrobiologyDx, and what we see in our own patients. If you have not yet read our foundational overview, it pairs well with this one: Chronic Inflammatory Response Syndrome (CIRS).
What Is MARCoNS?
MARCoNS stands for Multiple Antibiotic-Resistant Coagulase-Negative Staphylococci. To unpack that, it helps to know how microbiologists sort the staph family. Staphylococcus is a large genus of common, mostly harmless bacteria that live on our skin and mucous membranes. A simple lab test — the coagulase test — splits the genus into two useful buckets. Coagulase-positive staph is mainly Staphylococcus aureus, the more aggressive, infection-causing branch. Coagulase-negative staph (CoNS) is usually gentler and includes species like S. epidermidis.
MARCoNS is the coagulase-negative branch that has become resistant to multiple classes of antibiotics. In the lab it is defined precisely: a coagulase-negative staph that shows resistance (or intermediate resistance) to two or more antibiotic classes. Notice what the test is not doing — it is not looking for an antibiotic to prescribe. The resistance panel is used purely to confirm that a colony qualifies as MARCoNS.
Crucially, MARCoNS is a colonizer, not an active infection. It sets up residence deep in the nasal passages — not the aggressive, tissue-destroying behavior of a classic staph infection. Think of it less like an invasion and more like squatters who move in and refuse to leave. In a healthy person that would barely register. In someone with CIRS, the problem is what that quiet colonization does to an immune system that is already dysregulated.
MARCoNS is uncommon in the general population — roughly 1–2% of healthy people carry it without consequence. But in people with CIRS, carriage rates run as high as 80–92%. If you have CIRS, MARCoNS is something to actively look for, not a footnote.
Why MARCoNS Matters in CIRS: The MSH Cycle
The reason Dr. Ritchie Shoemaker made MARCoNS eradication a formal step in his CIRS protocol comes down to a single hormone: alpha-melanocyte stimulating hormone (α-MSH). MSH is a small but powerful regulatory peptide made in the pituitary. It calms inflammation, helps defend against microbes, supports restful sleep and hormone balance, and helps protect the lining of the nose from unwanted colonizers. In CIRS, biotoxin-driven inflammation drives MSH down — and low MSH is behind much of the fatigue, brain fog, poor sleep, pain sensitivity, and hormone disruption that define the illness.
Here is where MARCoNS turns a bad situation into a self-reinforcing loop. These resistant bacteria are thought to release membrane-damaging toxins — described in the literature as exotoxins A and B — along with hemolysins that cleave and inactivate MSH. In other words, low MSH opens the door for MARCoNS to colonize, and once MARCoNS is established it drives MSH even lower. That is why patients so often describe hitting a wall: as long as the colony persists, MSH struggles to recover, and as long as MSH stays low, everything feels worse.
Low MSH lets MARCoNS in. MARCoNS then drives MSH lower still. Breaking that cycle is the whole point of treating it.
What counts as a “good” MSH number? Using LabCorp, a healthy reference range runs roughly 35–81. Our CIRS patients often sit below 20, and frequently below 8 (so low the lab can’t even measure it). The ideal target is 30 or above — at that level MSH itself becomes protective, guarding the nasal lining so well that a preventive spray is no longer needed. But we celebrate progress: moving someone from “less than 8” up into the 20s is a meaningful win, and MSH in the 20s can still manage the downstream hormones reasonably well.
New Research: Clearing MARCoNS Is Linked to Higher MSH
For years, the MSH–MARCoNS connection rested largely on Dr. Shoemaker’s clinical observations and a 2003 conference presentation. That picture is now being strengthened with real data. In April 2026, Dr. Margaret DiTulio (DNP, APRN, MBA) and Christian A. Navarro-Torres published a study in Frontiers in Endocrinology following 188 patients evaluated for CIRS. Each patient was measured at two points — before MARCoNS treatment and at follow-up at least six weeks later — and grouped by whether they had cleared MARCoNS by the follow-up swab.
Across the whole group, biomarkers moved in the right direction: α-MSH rose, MMP-9 fell, and VIP rose. But the crucial finding was about which marker tracked with clearing the bug. There was a significant, selective link between MARCoNS clearance and higher α-MSH — and notably not with MMP-9 or VIP. Patients who cleared MARCoNS saw their average α-MSH climb to about 20 pg/mL, while those who stayed MARCoNS-positive reached only about 16.6 pg/mL, from an essentially identical starting point (~8.5 pg/mL in both groups). In other words, everyone getting treated improved somewhat — but getting the MARCoNS out was specifically associated with the bigger MSH recovery.
DiTulio M, Navarro-Torres CA. “Clearance of multiple antibiotic-resistant coagulase-negative staphylococci is selectively associated with higher circulating α-melanocyte stimulating hormone in patients evaluated for chronic inflammatory response syndrome.” Frontiers in Endocrinology, 17 April 2026. Retrospective observational cohort, N = 188.
This is observational research — it shows association, not proof of cause — but the fact that the effect was specific to α-MSH (and not the other inflammatory markers) strengthens the long-held clinical picture: MARCoNS appears to hold MSH down, and getting it out gives MSH room to recover.
Dr. DiTulio also presented a companion talk at the 2026 CIRSx Global conference — “Lessons Learned from Testing and Treating MARCoNS: Important Findings from 177 Patient Experiences” — and it is her patient-level data that gives us the most honest picture yet of just how stubborn this organism can be. I had the privilege of meeting Dr. DiTulio and hearing her lecture in person at the recent CIRSx 2026 conference, and I came away having learned a great deal from her work; much of what follows is informed by that lecture. We’ll come back to those numbers below.
The Real Reasons It Won’t Clear
When a patient tells us their MARCoNS keeps coming back, we are almost always looking at one or more of four culprits. The first two — biofilm and ongoing exposure — account for the large majority of cases, and in our experience ongoing exposure is the single most likely reason of all. The other two, hidden structural reservoirs and testing pitfalls, explain most of the rest.
Biofilm
A protective slime shield the bacteria build over themselves, blocking antimicrobials from reaching the colony.
Ongoing exposure
Still-low MSH plus continued mold or environmental exposure means you re-colonize almost as fast as you clear.
Structural reservoirs
A deviated septum, dental cavitations, or other protected niches shelter bacteria a spray can’t reach.
Testing & timing
A swab that didn’t reach deep enough, or re-culturing at the wrong moment, can mislead in both directions.
Biofilm — the slime shield
MARCoNS rarely floats around as tidy, exposed bacteria. Instead it builds a biofilm — a self-made matrix of slime that glues the colony to the nasal lining and forms a physical barrier antimicrobials struggle to penetrate. This is a large part of why these organisms read as “multi-resistant” in the first place: it is not only that the bacteria have resistance genes, it is that the drug can’t get to them.
Just how common is biofilm here? In an in-vitro study run by MicrobiologyDx, 25 of 26 MARCoNS-positive nasal cultures were biofilm-positive. In other words, biofilm is close to a defining feature of MARCoNS, not an occasional complication. That is why effective treatment is almost always a “one-two punch”: an agent that breaks down the biofilm paired with one that kills the exposed bacteria. EDTA is the workhorse biofilm disruptor — it chelates the minerals the matrix depends on, dissolving the shield so an antimicrobial (silver, botanicals, or an antibiotic) can finally reach its target. Xylitol works differently but toward the same end, helping loosen bacterial adherence while starving the bugs of the sugar they mistake for food.
When MicrobiologyDx grades a biofilm as strong (3+), Dr. Musto and Dr. DiTulio both suggest simply treating longer — often eight to nine weeks instead of six — because a thicker shield takes more time to wear down. A stronger biofilm is not a reason to give up; it is a reason to be patient.
Ongoing exposure — the most likely reason of all
This is the one we come back to again and again. Remember the MSH cycle: MSH is what protects your nasal lining from re-colonization. If you are still being exposed — a water-damaged home or office, a car, a workplace, even a single moldy room you spend hours in — your MSH stays suppressed, and MARCoNS can move back in within days to a couple of weeks of finishing treatment.
This creates a genuinely confusing picture that fools a lot of people. As Dr. Musto has explained, when a patient clears MARCoNS and then re-tests positive, it is usually not that the spray “stopped working” or that the bug developed resistance to it. Look at the susceptibility pattern and you’ll often find a different strain — meaning the patient was simply re-colonized from their environment. The treatment worked; the exposure undid it.
We’ve heard patients describe using their re-swab almost as an environmental detector: they clear MARCoNS when they’re out of exposure, then test positive again every time they spend real time in a bad building. If your MARCoNS clears and returns in lockstep with where you’re living or working, that is a loud signal to “double-click” on your exposure before blaming the treatment.
Exposure isn’t only about buildings. Two quieter sources deserve attention:
- Pets. Dogs and cats can carry MARCoNS — and interestingly, stray animals generally don’t. That tells us the pet usually caught it from a person in the household. If you’re giving your dog a hundred face-kisses a day, you may be trading it back and forth. Clear your own, practice good hygiene, and your pet’s own immune system can usually clear theirs once you stop re-inoculating each other.
- Personal items. Nasal spray nozzles, nose-hair trimmers, toothbrushes. Wipe the spray nozzle with an alcohol swab after each use, disinfect trimmers, and change toothbrush heads regularly so you’re not re-seeding yourself.
Hidden structural reservoirs
Sometimes a patient is genuinely out of exposure, their biofilm has been addressed, and MARCoNS still won’t fully clear. In those cases we start looking for a protected niche — a place in the anatomy where bacteria can hide from a topical spray and keep re-seeding the nose. This is something we see often in practice, and it’s frequently overlooked.
The usual suspects:
- A deviated septum, swollen mucosa, or other structural obstructions. Remember that the medication has to reach high up in the nasal passage, not just inside the nostril. A deviated septum may let the spray reach one side easily while the other side never gets adequate coverage. Even seasonal allergies count here — swollen, congested nasal linings physically block the spray from getting where it needs to go. When someone isn’t clearing, an ear-nose-throat exam (in person, or via referral for remote patients) becomes genuinely important.
- Dental cavitations and prior extraction sites. Jawbone defects — often from old extractions, root canals, or wisdom-tooth sites — can act as reservoirs, where bacteria have consumed the soft tissue and are thinning the surrounding bone. These sites overlap with facial pain, sinus symptoms, and headaches. A biologic dentist, oral surgeon, endodontist, or periodontist can evaluate them with a cone-beam CT — a quick, five-minute scan that measures bone thickness at old extraction sites. If the oral reservoir isn’t addressed, the nose keeps getting re-seeded.
- Deeper sequestration. The research raises the possibility that these staph species can be internalized into host cells (including bone and endothelial cells), which would help explain why some colonies survive even a well-run topical protocol.
The practical takeaway from Dr. DiTulio’s presentation is blunt and worth repeating: preventing re-colonization requires more than an antimicrobial spray. When MARCoNS is truly persistent, it’s a systems problem — adherence, anatomy, biofilm, and extra-nasal reservoirs may all need attention together.
Testing and timing pitfalls
Sometimes the “won’t clear” problem is really a testing problem. MARCoNS lives deep — the nasal passages run straight back toward the middle of the head, not up — and a swab that doesn’t reach far enough can miss it entirely. A negative that came from a shallow, comfortable swab may simply be a false negative; a proper deep swab reaches the back and is scrubbed against the tissue to collect the colony.
Timing matters just as much. The refined recommendation is to re-culture while you are still on the spray (roughly a week before finishing a course), because if you stop treatment and wait several weeks to re-test, a low-MSH patient may have re-colonized by then — making a successful treatment look like a failure. And after a confirmed clearance, you don’t simply stop: most protocols step the spray down from three times a day to twice a day as a maintenance dose (commonly low-dose EDTA around 0.2–0.25%) to hold the line while MSH slowly recovers. Skipping this maintenance phase is a common reason MARCoNS “comes back.”
This becomes an ongoing management relationship. If a patient has cleared, tapered to prophylaxis, and their MSH has been climbing — then a later lab shows MSH dropping again — that’s a signal they may have “broken through” their prophylaxis (often a fresh exposure while traveling). The move is to re-culture and, if positive, return to full three-times-daily treatment until it clears again. MARCoNS management is rarely one-and-done; it’s a dial you adjust as MSH and exposures change.
The Reality of Clearance: What 177 Patients Show Us
If there is one thing we want you to take from this article, it’s this: MARCoNS is hard to clear, and that is not your fault. Dr. DiTulio’s review of 177 patient experiences put real numbers to this. When she looked at first-pass clearance rates for the topical strategies her patients used, even the best-performing single approaches cleared MARCoNS only about a quarter of the time. Many combinations, especially at small sample sizes, cleared it far less often.
| Topical strategy | First-pass clearance rate | Sample |
|---|---|---|
| Xylitol + grapefruit seed extract | n = 52 | |
| Xylitol + GSE + herbs | n = 4 | |
| Ionic silver 50 ppm | n = 32 | |
| GSE + silver + herbal blend | n = 27 | |
| Xylitol + oregano + bee propolis | n = 11 | |
| EDTA 0.25% + silver 50 ppm | n = 6 | |
| EDTA 0.5% + silver 50 ppm | n = 6 | |
| EDTA 1% + ionic silver 75 ppm | n = 7 | |
| Mupirocin 0.2% (alone) | n = 1 |
Selected results from Dr. Margaret DiTulio’s 177-patient review, 2026 CIRSx Global conference. A few formulations showed 100% clearance but only in a single patient (n=1), so those numbers are not meaningful. Bars are illustrative.
Read that table the right way. It does not mean these treatments don’t work — it means one round with one agent often isn’t enough. Real-world clearance usually comes from combining a biofilm disruptor with an antimicrobial, treating long enough (especially with strong biofilm), addressing exposure and reservoirs, and running more than one course. If your first attempt didn’t clear it, you are squarely in the majority, and that is exactly what the data would predict.
Looking across the individual treatment courses in her review, Dr. DiTulio found a helpful way to think about the population: roughly 43% of patients cleared MARCoNS reasonably easily — within one, two, or three attempts — while about 28% needed more than three courses. That second group is the one this article is really written for. It is a real and sizable subset, not a handful of outliers, and it is where the reasons above (biofilm, exposure, reservoirs) truly earn their keep.
Some patients test negative for MARCoNS at baseline even with low MSH. Often that’s because they’re colonized with Staph aureus instead — the “bigger dinosaur” in the nasal terrain, which physically crowds MARCoNS out. A negative MARCoNS swab doesn’t automatically mean a healthy nose; it can simply mean a different colonizer is holding the territory.
The Treatment Landscape
There is no single “right” MARCoNS spray — which is precisely why so many options exist. Every one of them is aiming at the same two jobs: break the biofilm and kill the bacteria. Here is how the common strategies compare.
| Strategy | How it works | Notes |
|---|---|---|
| EDTA + silver | EDTA dissolves biofilm; ionic silver is a broad antimicrobial (kills gram-positive, gram-negative, mold, yeast) | The most popular prescription combination — a true one-two punch. Ionic silver around 50 ppm is a common target. |
| Xylitol + grapefruit seed extract (e.g. Xlear) | Xylitol loosens biofilm adherence and starves bacteria; GSE kills broadly | Available over the counter and affordable. In DiTulio’s data this was among the better-performing single strategies. Coptis (an herbal extract) can be added for extra killing power. |
| BEG spray | Bactroban (mupirocin) + EDTA + gentamicin — two antibiotics plus a biofilm disruptor | The historical standard. Powerful, but see the caveats below — we generally do not reach for it first. |
| Colloidal / ionic silver (alone) | Broad-spectrum antimicrobial | Well tolerated and low-cost; useful when a prescriber isn’t available. Keep it away from saline rinses by 2–3 hours (saline inactivates ionic silver). |
| Nebulizing | Delivers the antimicrobial (e.g. silver) as a fine mist that reaches deeper into the upper nasal passage than a spray | A practical option for structural obstructions or long-standing sinus involvement: an ordinary nebulizer (even an old childhood-asthma unit with fresh tubing and an infant mask) works — keep the mouth closed and breathe in through the nose. |
| Light therapy (adjunct) | Blue light is antimicrobial; red light is anti-inflammatory and supports tissue healing | Emerging. Nasal blue-light probes (e.g. Vielight) aim to reduce microbial burden; red light supports irritated nasal tissue. Promising but not yet studied specifically for MARCoNS — an adjunct, not a stand-alone cure. |
| Supportive adjuncts | Tissue healing & comfort | Vitamin E oil for irritated tissue, and gentle titration to avoid herx-type reactions. |
Titrate up slowly. Jumping straight to a full dose (for some sprays, four sprays per nostril several times daily) can trigger sharp headaches, light sensitivity, and irritation. Starting low, then stepping up over a week or two, usually resolves this. A little pink-tinged mucus can happen with these sprays and is generally not alarming — but always report reactions to your provider. A dab of vitamin E oil in the nostrils, or your clinician’s guidance, can ease the irritation.
A note on the silver-toxicity worry, because it comes up constantly: the blue-gray skin discoloration people fear (argyria) requires enormous, sustained silver intake. By Dr. Musto’s calculation, reaching that threshold would take something like 3,000 six-week cycles of ionic silver at typical nasal doses — effectively decades of continuous full-dose use. At the doses used for MARCoNS, the risk is very low. Ionic silver is also not a “heavy metal” in the toxicological sense often implied online.
Innovative adjuncts worth watching
For patients who are struggling to clear, it’s worth keeping an eye on newer adjunctive tools. One that’s generating interest is intranasal light therapy. Here it’s important to keep two colors straight: blue light is the antimicrobial one — companies such as Vielight make a small nasal probe designed to deliver blue light into the nasal passage to help lower microbial burden — while red light is prized for its anti-inflammatory and tissue-healing effects and can help soothe nasal tissue irritated by months of sprays. These are adjuncts, not stand-alone cures, and rigorous data specific to MARCoNS is still lacking. But for the stubborn cases, they represent the kind of gentle, additive approach we like to keep on the radar while the research catches up.
A Word on BEG Spray — and Why We Don’t Reach for It First
BEG nasal spray — Bactroban (mupirocin) 0.2%, EDTA 1%, and Gentamicin — has been the historically recognized MARCoNS treatment in the Shoemaker community for around two decades. The EDTA dissolves the biofilm; the two antibiotics attack the exposed bacteria. It can be very effective, and for the right patient it’s a reasonable option.
But we generally do not use it straight up as a first-line treatment, for a few reasons:
- Resistance stewardship. BEG is a “nuke.” Good antimicrobial practice is to reach for the smallest effective tool first — if you lead with your most powerful antibiotic combination and it doesn’t work, you’ve narrowed your future options. Leaning on antibiotic sprays as the default raises legitimate concerns about further resistance in an organism already defined by it.
- Herx potential. BEG is potent enough that many patients experience a strong die-off (“herx”) reaction — worsened brain fog and fatigue as the colony breaks down. It also kills broadly, including beneficial organisms in the nasal microbiome.
- Compounding inconsistency. The original BEG formula uses gentamicin at just 0.025%. Many pharmacies compound it far higher — sometimes 0.1–3% — which is where reports of bloody noses and ringing in the ears come from. If BEG is used, the gentamicin concentration should be specified carefully.
Our preference is usually to start with gentler, biofilm-oriented combinations — xylitol and grapefruit seed extract, ionic silver with EDTA, botanical agents like Coptis — reserving the heavier antibiotic sprays for when they’re truly needed. It’s worth adding Dr. Musto’s important nuance here: much of what looks like “BEG resistance” in practice is actually re-colonization from ongoing exposure, not the spray losing potency. Which brings the whole discussion back to where it started — exposure first.
When It Still Won’t Clear: Look Beyond MARCoNS
If you’ve addressed biofilm, confirmed you’re out of exposure, checked for structural reservoirs, and MARCoNS still won’t budge — or if you clear it and symptoms don’t improve — it may be time to widen the lens. MARCoNS is rarely the only thing living in a dysregulated nose.
Both Dr. DiTulio’s presentation and clinicians like Christian Navarro-Torres point to co-colonizers that can drive symptoms alongside (or instead of) MARCoNS:
- Other bacteria — Actinobacteria (actinomycetes) and endotoxin-producing gram-negatives such as Klebsiella. When a culture shows a gram-negative like Klebsiella alongside (or instead of) MARCoNS, it makes sense to choose a more aggressive agent that covers gram-negatives well — a silver-containing or straight-silver product. Our deeper dive on the bacterial side lives here: Actinomycetes, CIRS & Biotoxin Illness.
- Toxin-producing fungi — Aspergillus, Penicillium, and Cladosporium can share the same real estate (a fungal culture is an add-on that must be specifically requested). Note that in CIRS we avoid prescription antifungals, which carry their own problems — but silver is a useful antifungal that doesn’t cause those issues, another reason it earns its place in the toolkit.
The standard MARCoNS swab (from MicrobiologyDx) is excellent at answering “is MARCoNS here, how strong is the biofilm, and is there fungus?” But it isn’t designed to identify everything in your nose. This is exactly where a broader test earns its place.
The Sinus Key test from MicrogenDX uses DNA sequencing to identify essentially any species it can detect in a nasal swab — giving a much fuller picture of the nasal microbiome than a targeted MARCoNS culture. It’s a different company and a different question: not just “do I have MARCoNS?” but “what is actually living in my nose?” We keep these kits in the office — if you’ve tested and treated MARCoNS more than once and still feel stuck, this is often the next step we reach for.
The Last Resort: Is Your MARCoNS the Kind That Actually Matters?
There is one more layer worth understanding, and it may be the most important reframe of all for a truly stubborn case. In a 2026 discussion on the BetterHealthGuy podcast, Dr. Ritchie Shoemaker — the physician who defined the CIRS protocol — made a striking point: not all MARCoNS is created equal. In his view, MARCoNS becomes a genuine problem mainly when it produces a class of compounds called polycyclic ether toxins. When it does, it must be eradicated. When it doesn’t, he described MARCoNS as “just along for the ride” — needing only a short course of treatment rather than months of escalating effort.
How do you tell the two apart? This is where GENIE testing (Genomic Expression: Inflammation Explained — a transcriptomic test that reads how your genes are actually expressing right now) enters the picture. Dr. Shoemaker linked the toxin-producing behavior of MARCoNS to specific findings on GENIE, notably around mitochondrial ribosome (“mitoribosome”) markers. In practical terms, GENIE can help reveal whether a person’s persistent MARCoNS is the toxin-producing kind that truly needs aggressive eradication — or whether the body is better served by letting the normal nasal flora crowd it back out.
He also flagged a mechanism that makes some MARCoNS especially hard to clear: these bacteria readily absorb resistance genes from other organisms, and the use of antifungal drugs can drive MARCoNS to mutate into more resistant forms. Between toxin production and acquired resistance, there is a real subset of patients for whom a particular MARCoNS strain is exceptionally difficult to eradicate.
The takeaway we draw from this: if you have chased MARCoNS through multiple treatment rounds without success, GENIE testing can serve as a last-resort tool — not to treat the bug harder, but to answer a smarter question: is this MARCoNS actually the toxin-producing strain that’s driving your illness and worth continued aggressive treatment, or is it a passenger you can stop chasing? For the right patient, that single insight can end months of frustration. GENIE is ordered through progenedx.com and is best interpreted with a knowledgeable practitioner.
Our Approach at Tree of Light Health
We treat MARCoNS the way we treat everything in CIRS — as one piece of a larger terrain, not an isolated bug to be nuked. When someone comes to us stuck on this step, here is how we think it through:
- Exposure first, always. Before we escalate treatment, we make sure you are genuinely out of exposure. Ongoing exposure is the most common reason MARCoNS won’t clear, and no spray outruns a moldy building.
- Confirm with a proper deep swab and, when the story doesn’t add up, a broader Sinus Key panel to see the whole nasal microbiome.
- Target biofilm and bacteria together — usually with gentler, botanical and silver/EDTA-based combinations first, treating longer when biofilm is strong, and reserving antibiotic sprays like BEG for when they’re truly warranted.
- Hunt for hidden reservoirs — deviated septum, dental cavitations, and co-colonizers — when clearance stalls despite good compliance.
- Support the terrain — binders, biofilm support, drainage, and nasal-tissue healing — so your own immune system can finish the job and MSH can recover.
Frequently Asked Questions
Can I clear MARCoNS if I’m still living somewhere with mold?
Realistically, it’s very difficult. Ongoing exposure keeps MSH suppressed, and low MSH is what leaves the nasal lining open to re-colonization — often within days to a couple of weeks. This is why getting out of exposure (and using binders) generally comes before the MARCoNS step in the protocol. If you must treat while still in exposure for some reason, do it under a clinician’s guidance and expect that maintenance will be essential.
My swab came back negative but I still feel awful. Could it be a false negative?
Possibly. MARCoNS lives deep — the nasal passage runs straight back toward the center of the head, not up. A swab that didn’t reach far enough (it should feel like it’s almost touching the back and be scrubbed against the tissue) can miss the colony. If a negative result came from a shallow, painless swab, it may be worth repeating with proper depth, ideally in-office.
Is the silver in these sprays going to turn my skin blue?
At the doses used for MARCoNS, that risk is very low. Argyria — the blue-gray discoloration people worry about — requires massive, sustained silver exposure. By one microbiologist’s calculation you’d need the equivalent of thousands of six-week cycles to approach the threshold. Ionic silver is also not a “heavy metal” in the way that phrase is usually meant. As with anything, use it as directed and keep it away from saline rinses by a couple of hours.
Why does my MARCoNS keep coming back after I clear it?
The three usual reasons: (1) ongoing exposure keeping MSH low, (2) a persistent biofilm that was suppressed but not fully eradicated, and (3) a reservoir re-seeding you — a dental cavitation, a pet, or personal items like a spray nozzle or toothbrush. Skipping the maintenance-dose phase after clearance is another common culprit. If it keeps returning, the answer is usually found outside the spray bottle.
Do my pets need to be treated?
Sometimes. Dogs and cats in the home can carry MARCoNS — and since strays generally don’t, the pet most likely got it from a person in the household. Good hygiene plus clearing your own colonization usually lets a healthy pet clear theirs. Talk to your provider (and your vet) if you suspect a household ping-pong effect.
How is MARCoNS different from a sinus infection?
MARCoNS is a colonization, not an active infection, so its effects are generalized (fatigue, brain fog, plateau in recovery, easy relapse) rather than classic sinus-infection symptoms. Many people do have nasal symptoms too, but the hallmark is feeling stuck — better than you were, but not all the way well — alongside the other features of low MSH.
Stuck on MARCoNS? Let’s Figure Out Why.
If you’ve tried to clear MARCoNS and it just won’t go — or it keeps coming back — there is almost always a findable reason: a biofilm that needs more time, an exposure you haven’t fully escaped, or a hidden reservoir. We keep Sinus Key (MicrogenDX) kits in the office and can help you map out the full picture. Reach out and let’s get you moving again.
Looking for biofilm and detox support? Explore AquaLaurin for biofilm disruption and our Immune & Detox Support collection.
living. holistic. care.
References & Further Reading
- DiTulio M, Navarro-Torres CA. Clearance of multiple antibiotic-resistant coagulase-negative staphylococci is selectively associated with higher circulating α-melanocyte stimulating hormone in patients evaluated for chronic inflammatory response syndrome. Frontiers in Endocrinology. 2026 Apr 17. doi:10.3389/fendo.2026.1728408
- DiTulio M. Lessons Learned from Testing and Treating MARCoNS: Important Findings from 177 Patient Experiences. Presentation, 2026 CIRSx Global Annual Conference, Omni Fort Lauderdale.
- Butt HL, Dunstan RH, McGregor NR, Roberts TK, Zerbes M, Klineberg IJ. An association of membrane-damaging toxins from coagulase-negative Staphylococcus and chronic orofacial muscle pain. J Med Microbiol. 1998;47:577–84.
- Metcalf LN, McGregor NR, Roberts TK. Membrane-damaging toxins from coagulase-negative Staphylococcus are associated with self-reported temporomandibular disorder (TMD) in patients with chronic fatigue syndrome. J Chronic Fatigue Syndrome. 2004;12(3):25–43.
- Shoemaker RS, Hudnell K, House D, Domenico P. Association of nasal carriage of methicillin-resistant and multiple antibiotic-resistant coagulase-negative staphylococci with deficiency of alpha-MSH in chronic fatigue syndrome. Presentation, American Society for Microbiology, 2003.
- Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014;27(4):870–926. doi:10.1128/CMR.00109-13
- Khalil H, Williams RJ, Stenbeck G, Henderson B, Meghji S, Nair SP. Invasion of bone cells by Staphylococcus epidermidis. Microbes Infect. 2007;9:460–465.
- Lipton JM, Catania A, Ichiyama T. Marshaling the anti-inflammatory influence of the neuroimmunomodulator α-MSH. Physiology. 2000;15:192–5.
- Dooley M, Vukelic A, Jim L. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. Ann Med Surg. 2024;86:7248–54.
- Musto JD, Hrabec G, Moin E, Dashore JA. Report on the Effectiveness of the Antimicrobial Formula 1 NSB in Treating Multiple Antibiotic-Resistant Coagulase-Negative Staphylococcus (MARCoNS). MicrobiologyDx, Bedford MA, 2020.
- Nutrition with Judy (Cho J) interviews with Dr. Joseph Musto, MicrobiologyDX — MARCoNS, chronic sinus infections, and mold toxicity. YouTube.
- MARCoNS in CIRS: symptoms, testing, treatment options & why it keeps coming back. The CIRS Group podcast. YouTube.
- Shoemaker RC. GENIE Testing in CIRS. BetterHealthGuy Blogcasts, Episode 205 (interview with Scott Forsgren). betterhealthguy.com / YouTube.
- Navarro-Torres CA. Inside CIRS Lab and the Evolving Science of Biotoxin Illness. BetterHealthGuy Podcast, Episode 235 (interview with Scott Forsgren). betterhealthguy.com / YouTube.
- GENIE transcriptomic testing ordered via progenedx.com. MicrobiologyDx (microbiologydx.com); MicrogenDX Sinus Key.
